Interleukin said in July that it would liquidate its assets after laying off 63 percent of its workforce and suspending sales of its controversial genetic test.
With new gene sequencing panels, investigators made firm or possible diagnoses in almost one-third of undiagnosed autoinflammation and vasculitis cases.
The announcement comes three weeks after Interleukin said it was laying off 63 percent of its workforce and suspending sales of a controversial genetic test.
The decisions are part of the company's restructuring efforts after it was unable to extend deferral of its debt payment with its senior lender.
In Genome Biology this week: parainflammation found in some cancers, recurrent copy number changes affecting metabolic genes in cancer, and more.
In blood samples from infected individuals, a seven-gene signature apparently distinguishes between bacterial and viral culprits, a distinction important to antibiotic use.
The company's approach investigates the utility of high-density lipoproteins as molecular markers for multiple diseases, starting with cardiovascular.
The genetic testing firm is developing a plan to drive market adoption of its PerioPredict test for inflammation-related genes.
The FDA considers Interleukin Genetics' PerioPredict test and the DNA-CardioCheck test to be medical devices.
Researchers link personality traits to the expression of certain inflammation-related genes.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.